“Friday's First Moves: RH & KR Earnings Mixed, NVO Downgrade”Morgan Stanley
Morgan Stanley downgrades NVO to underweight; $40 PT implies downside from current levels due to growth concerns and patent cliff risks.
All right. And last but not least, we look at Novo Nordisk. I saw a downgrade and a price target below where we are now.